Sandostatin Injection is available as: sterile 1-mL ampuls in 3 strengths, containing 50, mcg octreotide (as acetate), and sterile 5-mL multi-dose vials in 2. Sep 3, Octreotide Acetate (Sandostatin ®) – Intravenous (IV) Dilution. Octreotide (Sandostatin) is the longer acting synthetic analogue of the naturally In patients with cancer and inoperable bowel obstruction octreotide rapidly.

Author: Shakazuru Sacage
Country: Mozambique
Language: English (Spanish)
Genre: Science
Published (Last): 5 August 2006
Pages: 328
PDF File Size: 15.42 Mb
ePub File Size: 12.84 Mb
ISBN: 929-5-70279-542-2
Downloads: 2257
Price: Free* [*Free Regsitration Required]
Uploader: Malakinos

Multiple subcutaneous injections at the same site within short periods of time should be avoided. The most frequent adverse reactions reported during octreotide therapy include gastrointestinal disorders, nervous dpsis disorders, hepatobiliary disorders, and metabolism and nutritional disorders.

Ochreotide lesions were not observed either in mice receiving daily s. Other oxtreotide reported adverse reactions were dizziness, localised pain, biliary sludge, thyroid dysfunction e. The volume of distribution is 0. Known hypersensitivity to the active substance or to any of the excipients listed ddosis section 6. Metabolism and nutrition disorders. Upward dose titration is frequently required. Step 7 After the saturation period, ensure plunger is pushed all the way down in the syringe Keep plunger pressed and shake vial moderately in a horizontal direction for a minimum of 30 seconds so the powder is completely suspended uniform milky suspension.

Step 6 Let vial stand for a minimum of 2 minutes and up to 5 minutes to ensure that the diluent has fully saturated the powder It is normal that the plunger rod may move up if there is overpressure in the vial At this stage, prepare patient for injection.

Dosing & Administration

In addition, cholelithiasis induced pancreatitis has been reported for patients on long-term Octreotide s. Now you can find the tools you need to help manage your patients, all in one place! Continue octreogide to refine. Depending on clinical response, effect on levels of tumour-produced hormones in cases of carcinoid tumours, on the urinary excretion of 5-hydroxyindole acetic acidand on tolerability, dosage can be gradually increased to 0.


In octtreotide patients, computed tomography scanning suggests a slowing or arrest of progression of the tumour, or even tumour shrinkage, particularly of hepatic metastases. Patients should not breast-feed during Octreotide treatment.

Acute and repeated dose toxicology, genotoxicity, carcinogenicity and reproductive toxicology studies in animals revealed no specific safety concerns for humans. Each 1 ml of solution for injection contains micrograms of Octreotide as octreotide acetate. Dyspepsia, vomiting, abdominal bloating, steatorrhoea, loose stools, discolouration of faeces. Cardiovascular related events Common cases of bradycardia have been reported.


Administration of Sandostatin may result in improvement of symptoms, particularly of flushing and diarrhoea. Dyspnoea Cardiac disorders Common: Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: Do not warm artificially.

Bradycardia is a common adverse reaction with somatostatin analogues. Show table of contents Hide table of contents 1. The biochemical characteristic of these tumours is overproduction of vasoactive intestinal peptide VIP. In patients with functional tumours of the GEP endocrine system, octreotide, because of its diverse endocrine effects, modifies a number of clinical features. The dose most commonly found to be effective is mcg t. Reevaluate every 6 months.

SANDOSTATIN Dosage & Rx Info | Uses, Side Effects – MPR

No causal relationship to octreotide is suspected for these cases. To email a medicine you must sign up and log in. Impaired renal function did not affect the total exposure AUC to octreotide administered as s.


Sites should be rotated in a systematic manner. VIPomas Daily dosages of mcg in divided doses are recommended during the initial 2 weeks of therapy range mcg to control symptoms of the disease. Repeat moderate shaking for another 30 seconds if the powder is not completely suspended. To view the changes to a medicine you must sign up and log in.

Oesophageal varices Since, following bleeding episodes from oesophageal varices, there is an increased risk for the development of insulin-dependent diabetes or for changes in insulin requirement in patients with pre-existing diabetes, an appropriate monitoring of blood kctreotide levels is mandatory. The frequency of gastrointestinal adverse events is known to decrease over time with continued treatment. Therapy with proton pump inhibitors or H2 receptor blocking agents generally controls gastric acid hypersecretion.

Diarrhoea, abdominal pain, octreoide, constipation, flatulence. This medicinal product must not be mixed with other medicinal products, except those mentioned in section 6.

Dosing Sandostatin® LAR®

However, diarrhoea, which is also a prominent symptom, may not be adequately alleviated by proton pump inhibitors or H2 receptor blocking agents. In patients with inoperable benign or malignant tumours, glycaemic control may be improved without concomitant sustained reduction in circulating insulin levels.

Step 11 Ocfreotide safety guard over the needle by either: